CRISPR and Cas Gene Market
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033
13. Dezember 2024 09:27 ET | Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Gene Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.This report describes and...
Gene Editing Market
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
29. November 2024 04:43 ET | Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (GRNA Synthesis & Vector Construction), Technique, Technology...
Cell and Gene Therapy Tools and Reagents Market
Cell and Gene Therapy Tools and Reagents Market Report 2024 - Driving Medical Advances: Cell and Gene Therapy Tools Market to Hit $16.7 Billion by 2029
29. November 2024 04:24 ET | Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering.The Cell and Gene Therapy Tools and...
22157.jpg
CRISPR Gene Detection and Diagnostic Markets Report 2024: Unlimited Potential from a Startling Technology, Simultaneous Detection of Multiple Gene Targets Opens Up Huge Market Opportunities
29. November 2024 04:01 ET | Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Gene Detection and Diagnostic Markets by Research, Clinical Lab, Consumer, Public Service & Other with Executive and Consultant Guides. 2023...
Intellia.jpg
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
25. November 2024 07:30 ET | Intellia Therapeutics, Inc.
CAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
sns insider pvt ltd.png
Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider
22. November 2024 09:00 ET | SNS Insider pvt ltd
Austin, United States, Nov. 22, 2024 (GLOBE NEWSWIRE) -- According to SNS Insider, The Genome Editing Market, valued at USD 7.99 billion in 2023 and is projected to reach USD 32.72 billion by 2032,...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
20. November 2024 16:00 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Intellia.jpg
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
16. November 2024 10:16 ET | Intellia Therapeutics, Inc.
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater...
Intellia.jpg
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
07. November 2024 07:30 ET | Intellia Therapeutics, Inc.
Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on...
Caribou_logo.png
Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update
06. November 2024 16:05 ET | Caribou Biosciences, Inc.
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior...